profit from every $100 of sales.
$0$100
Amgen
$465.67-0.30% today
+38.6% in 1 year
1-year low $313.851-year high $478.48
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $32.67 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Amgen sold, what it kept, and what it did with the cash.
Sales went from $26.3 billion in 2022 to $36.8 billion in 2025, with $7.71 billion of profit last year.
SalesProfit
Amgen handed back 63% of the cash it generated last year.
$5.1B
Free cash flow 2025$8.1B
Bought back its own shares$0
Paid as dividends$5.1B
Cash vs. debt$9.1B vs. $54.6B
Amgen vs. similar companies
Amgen grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Amgen | 32.7× · Expensive | ||
 Eli Lilly | 62.3× · Very expensive | ||
 Johnson & Johnson | 25.7× · Fair price | ||
 AbbVie | 123.4× · Very expensive | ||
 Roche | 25.5× · Fair price |
Compare Amgen with AbbVie · Bristol-Myers Squibb · Gilead Sciences · Intuitive Surgical · Johnson & Johnson · Eli Lilly · Medtronic · Merck &
AI analysis
An AI analyst reads Amgen's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 25,424 | 25,979 | 26,323 | 28,190 | 33,424 | 36,751 | |
| 19,265 | 19,525 | 19,917 | 19,739 | 20,566 | 24,714 | |
| 9,139 | 7,639 | 9,566 | 7,897 | 7,258 | 9,080 | |
| 12,996 | 11,296 | 12,169 | 14,801 | 13,356 | 16,898 | |
| 7,264 | 5,893 | 6,552 | 6,717 | 4,090 | 7,711 | |
| 12.31 | 10.28 | 12.11 | 12.49 | 7.56 | 14.23 | |
| 75.8% | 75.2% | 75.7% | 70.0% | 61.5% | 67.2% | |
| 35.9% | 29.4% | 36.3% | 28.0% | 21.7% | 24.7% | |
| 28.6% | 22.7% | 24.9% | 23.8% | 12.2% | 21.0% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 62,948 | 61,165 | 65,121 | 97,154 | 91,839 | 90,586 |
| Cash | 6,266 | 7,989 | 7,629 | 10,944 | 11,973 | 9,129 |
| Total debt | 32,986 | 33,309 | 38,945 | 64,613 | 60,099 | 54,604 |
| Total liabilities | – | – | 61,460 | 90,922 | 85,962 | 81,928 |
| 9,409 | 6,700 | 3,661 | 6,232 | 5,877 | 8,658 | |
| 590 | 573 | 541 | 538 | 541 | 542 | |
| 17.5% | 15.6% | 16.2% | 12.0% | 9.3% | 14.6% | |
| 77.2% | 88.0% | 179.0% | 107.8% | 69.6% | 89.1% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 10,497 | 9,261 | 9,721 | 8,471 | 11,490 | 9,958 | |
| 608 | 880 | 936 | 1,112 | 1,096 | 1,858 | |
| 9,889 | 8,381 | 8,785 | 7,359 | 10,394 | 8,100 | |
| Dividends paid | 3,755 | 4,013 | 4,196 | 4,556 | 4,832 | 5,124 |
| 3,486 | 4,975 | 6,360 | 0 | 200 | 0 | |
| 330 | 341 | 401 | 431 | 530 | 494 |
Valuation
- 32.7×
- 20.8×
- 11.11
- 28.8×
- 6.9×
- 31.1×
- 17.6×
- 3.2%
- 3.1%
- 2.9%
Profitability
- 67.2%
- 24.7%
- 21.0%
- 46.6%
- 15.0%
- 13.4%
- 89.4%
- 8.4%
- 17.4%
- 20.2%
Growth
- +7.6%
- +2.9%
- −22.1%
- +8.3%
- +0.1%
Financial health
- 2.7×
- 6.31
- 62.0%
- 4.3×
- 1.14
- 1.01
- 0.40
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 15%of 946
Top 16%of 872
Bottom 42%of 563
Bottom 37%of 868
Top 33%of 986
What analysts expect
- Average price target
- $350.12
- Range
- $185.00 – $432.00
- 12 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | 5.15 | 4.77 | +8.0% |
| Feb 3, 2026 | 5.29 | 4.73 | +11.8% |
| Nov 4, 2025 | 5.64 | 5.02 | +12.4% |
| Aug 5, 2025 | 6.02 | 5.28 | +14.0% |
| May 1, 2025 | 4.90 | 4.27 | +14.8% |
| Feb 4, 2025 | 5.31 | 5.04 | +5.4% |
| Oct 30, 2024 | 5.58 | 5.11 | +9.2% |
| Aug 6, 2024 | 4.97 | 4.98 | −0.2% |
2.9%of the share price, paid each year
On $1,000 invested$29a year at today's yield, before tax
+8.3%2020 to 2025
Raised10 yearsin a row, in our data
Paid per share, each year
$3.16 in 2015 → $9.52 in 2025
How safe it looks
66.5% of its profit
Room to growStretchedMore than it earns: 63.3%
News
Amgen boosts 2026 guidance following Q3 beatsSeeking Alpha · Nov 3, 2026Dow Jones Biotech Giant Amgen Breaks Out Ahead Of Q3 Earnings ResultsYahoo Finance · Oct 27, 2026When Amgen's Forecast And Chart Say The Same Thing, Pay AttentionYahoo Finance · Oct 17, 2026Is Amgen Stock Increasing Your Market Risk?Yahoo Finance · Oct 17, 2026AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilotSeeking Alpha · Oct 3, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
46No pass
Benjamin Graham
26No pass
Philip Fisher
56No pass
Peter Lynch
18No pass
Joel Greenblatt
20No pass
Charlie Munger
55No pass
Terry Smith
55No pass
Questions about Amgen
Is Amgen a good stock to buy?
A strong, very profitable business, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Amgen AI analysis
What does Amgen do?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It is in Drug Manufacturers - General, based in Thousand Oaks, CA, United States, with 31,500 employees.
Does Amgen pay a dividend?
Yes. At today's price the dividend is 2.9% a year, about 66% of its yearly profit. In 2025 it paid out $5.12 billion in dividends.
Is Amgen stock halal?
Yes. Amgen passes our halal screen: its business is permitted and its debt is 22% of its market value, under the 30% limit. How we check
How has Amgen stock done over the past year?
Up 38.6% over the past twelve months, to $465.67. It traded between $313.85 and $478.48 and is 2.7% below its high.
Who are Amgen's competitors?
The largest listed companies in the same industry are Eli Lilly, Johnson & Johnson, AbbVie and Roche. The peers table on this page compares their profit, growth and price with Amgen's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.